Sartorius (SRT3) AI Stock Analysis

• Market Cap: €12.13B
• Dividend Yield: 0.38%
• Average Volume (3M): 155.29K
• Price to Earnings (P/E): 135.2
• Beta (1Y): 1.71
• Revenue Growth: 3.80%
• EPS Growth: 25.21%
• Country: DE
• Employees: 13,573
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.22
• Shares Outstanding: 37,440,000
• 10 Day Avg. Volume: 198,804
• 30 Day Avg. Volume: 155,295
• PEG Ratio: 16.87
• Price to Book (P/B): 5.40
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 18.89
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €251.18
• Price Target Upside: 29.78% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 11

• Rating: 56 Neutral
• Price Target: €216.00 ▲(11.60%Upside)

The overall stock score for Sartorius is primarily impacted by its stable cash flow and asset management, providing some financial stability. However, declining profitability and overvaluation pose significant risks. The bearish technical indicators further contribute to a cautious outlook.

Positive Factors

Earnings Performance

Sartorius AG delivered a 7% beat on EBITDA compared to consensus, which is considered a positive result.

Growth Expectations

The guidance for EBITDA was raised to 30% at the high point, indicating strong performance expectations.

Negative Factors

Product Segment Performance

Lab products and services showed weakness with a decline in revenue and missed EBITDA estimates, highlighting concerns in equipment purchasing.

Sartorius Business Overview & Revenue Model

Company Description

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.

How the Company Makes Money

Sartorius AG generates revenue primarily through the sale of its bioprocess and laboratory products. In the Bioprocess Solutions division, the company provides equipment and consumables used in the production of biopharmaceuticals, serving clients such as pharmaceutical and biotech companies. This division is a major contributor to Sartorius's revenue, driven by the growing demand for biologics and the expansion of biomanufacturing facilities globally. The Lab Products & Services division complements this by offering a range of laboratory instruments and services to support research and quality control. Sartorius also engages in strategic partnerships and acquisitions to enhance its product offerings and expand its market reach, further boosting its revenue streams.

Sartorius Financial Statement Overview

Summary

Sartorius demonstrates stable cash flow and asset management, with strong cash generation capabilities. However, profitability has been pressured in recent periods, with declining margins and revenue growth. Increasing leverage could pose future risks if not managed carefully.

Income Statement

Sartorius shows a stable gross profit margin of around 45% to 50% over the periods, indicating efficient cost management. The net profit margin in the TTM stands at 3.63%, a drop from previous years, primarily due to decreased EBIT and net income. Revenue growth has been inconsistent, with a decline in 2025 TTM compared to the previous year. The EBIT and EBITDA margins have also contracted, pointing to reduced operational efficiency.

Balance Sheet

The company's debt-to-equity ratio increased slightly, reflecting higher leverage, which may pose financial risks. However, the equity ratio remains stable, suggesting a balanced capital structure. Return on equity has decreased to 4.62% in the TTM, indicating lower profitability for shareholders. While the company maintains solid asset management, rising liabilities could be a concern.

Cash Flow

Sartorius's operating cash flow has improved in the TTM, suggesting strong cash-generating ability. Free cash flow growth is robust, rising by approximately 21% compared to the previous period, indicating good cash management. The operating cash flow to net income ratio is elevated, reflecting strong cash conversion despite lower net income. Overall, cash flow management appears solid, supporting financial stability.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.38B	3.40B	4.17B	3.45B	2.34B
Gross Profit	1.52B	1.57B	2.20B	1.84B	1.21B
EBITDA	786.80M	873.10M	1.54B	945.12M	662.13M
Net Income	84.00M	205.20M	913.10M	426.98M	321.47M
Balance Sheet
Total Assets	10.10B	9.76B	6.98B	5.70B	4.70B
Cash, Cash Equivalents and Short-Term Investments	828.70M	394.20M	196.80M	360.99M	217.65M
Total Debt	4.56B	5.31B	2.54B	2.08B	2.09B
Total Liabilities	6.21B	7.00B	4.32B	3.98B	3.30B
Stockholders Equity	2.76B	2.07B	1.99B	1.26B	1.05B
Cash Flow
Free Cash Flow	566.30M	293.90M	211.60M	458.65M	271.27M
Operating Cash Flow	976.20M	853.60M	734.20M	865.81M	511.52M
Investing Cash Flow	-425.80M	-2.82B	-1.13B	-569.61M	-1.27B
Financing Cash Flow	-128.30M	2.17B	209.90M	-165.18M	907.47M

Sartorius Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 193.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:SRT3, the sentiment is Negative. The current price of 193.55 is below the 20-day moving average (MA) of 213.63, below the 50-day MA of 214.31, and below the 200-day MA of 226.29, indicating a bearish trend. The MACD of -4.73 indicates Positive momentum. The RSI at 31.06 is Neutral, neither overbought nor oversold. The STOCH value of 22.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:SRT3.

Sartorius Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	58 Neutral	£4.95B	6.56	-62.36%	103.85%	34.03%	6.31%
SRT3	56 Neutral	€12.13B	135.21	3.55%	0.38%	3.80%	25.21%
0DHC	―	€4.54B	28.66	7.48%	1.15%	―	―
0H9X	―	€13.48B	21.81	4.37%	3.13%	―	―
0OO9	―	€23.36B	55.91	6.28%	2.39%	―	―
0O14	―	€48.83B	17.33	9.74%	1.91%	―	―
SEMHF	―	$62.76B	27.09	11.14%	0.03%	―	―